Drotaverine hydrochloride
{logo}
No-Spa Forte is a spasmolytic medicine that reduces pain (painful spasms) in the abdominal and pelvic cavities, i.e., in the digestive tract (stomach and intestines), bile ducts, and urinary tract, as well as in the female reproductive system.
No-Spa Forte contains drotaverine hydrochloride as the active substance.
This substance is used for smooth muscle spasms of both nervous and muscular origin. The spasmolytic effect of drotaverine does not depend on the type of innervation and the location of the smooth muscles (digestive tract, urogenital system, circulatory system, and bile ducts).
The medicine is metabolized in the liver and excreted mainly in the urine and to a lesser extent through the digestive tract.
Before starting to take No-Spa Forte, discuss it with your doctor.
Caution should be exercised when taking No-Spa Forte:
Do not take the medicine during labor.
Tell your doctor about all medicines you are taking or have recently taken, as well as any medicines you plan to take.
Caution should be exercised when taking No-Spa Forte with levodopa (a medicine used for Parkinson's disease) due to the reduced effect of levodopa and increased tremors and stiffness.
No-Spa Forte can be taken with or without food.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor before taking this medicine.
Drotaverine passes through the placenta.
Do not take the medicine during labor.
It is not recommended to take this medicine during breastfeeding.
In therapeutic doses, drotaverine taken orally does not affect the ability to drive vehicles or operate machines.
If dizziness occurs, avoid potentially hazardous activities, such as driving or operating machines.
Each tablet contains 104 mg of lactose monohydrate.
If you have previously been diagnosed with an intolerance to some sugars, consult your doctor before taking the medicine.
Take this medicine always as directed by your doctor. If you are unsure, consult your doctor.
The package contains 48 or 50 tablets.
1 tablet contains 80 mg of drotaverine hydrochloride.
Adults:
The daily dose is 120 to 240 mg in 2 to 3 divided doses.
Use in children:
Clinical trials have not been conducted in children.
In case of necessity to use the No-Spa Forte medicine, 80 mg in children:
If you have taken a higher dose of the medicine than recommended, consult your doctor or pharmacist immediately.
Do not take a double dose to make up for a missed dose.
If you have any further doubts about taking this medicine, consult your doctor, pharmacist, or nurse.
Like all medicines, No-Spa Forte can cause side effects, although not everybody gets them.
Rare(may affect up to 1 in 1000 people):
Frequency not known(cannot be estimated from the available data):
If you experience any side effects, including any side effects not listed in the leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder or its representative in Poland.
Reporting side effects will help to gather more information on the safety of the medicine.
Keep the medicine out of sight and reach of children.
Store in a temperature below 25°C. Protect from light.
Do not use the medicine after the expiry date stated on the packaging.
The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The package contains 48 or 50 tablets of 80 mg each.
The tablets are yellow, oblong, and convex with a greenish or orange tint. On one side of the tablet, it says "NOSPA", and on the other, there is a dividing line.
Marketing authorization holder
Opella Healthcare Commercial Ltd.
Váci út 133. "E" building 3rd floor,
Manufacturer
Opella Healthcare Poland Sp. z o. o.
Branch in Rzeszów
ul. Lubelska 52
35-233 Rzeszów
Opella Healthcare Hungary Limited Liability Company
Levai u. 5 H-2112 Veresegyhaz
Hungary
To obtain more detailed information, contact the local representative of the marketing authorization holder:
Opella Healthcare Poland Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warsaw
Phone: +48 22 280 00 00
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.